Jefferies analyst Brian Tanquilut lowered the price target on HCA Healthcare Inc (NYSE: HCA) to $525.00 (from $590.00) while maintaining a Buy rating.

The analyst commented, "The set-up for HCA into the Q1 print was tough as weather dragged on volumes, but the Street was all over the place in modeling its earnings impact. Sure enough, Jan ice storms in the South dragged on SS admits by 0.3%, weak respiratory revs drove another 0.7% drag, and the de-leveraging impact of the top line shortfall caused a rare EBITDA miss. We keep our Buy given upcoming SDP approvals, savings/productivity gains from "resiliency" program, and strong FCF."